Please wait...
| ID | PMID | YEAR | Sequence | Name | Length | N-ter MOD | C-ter MOD | Linear/Cyclic | Chirality | Chem-MOD | Origin | Nature | Incubation Time | Concentration | Half Life | Units Half Life | Protease | Assay | Test Sample | Vivo/Vitro | Reference | Patent No. | Activity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8222093 | 1993 | Recombinant hirudin | 65 | Free | Free | Linear | L | None | Not available | Anticoagulant | Not reported | 1000ng/ml | 2 to 3 | Not mentioned | ELISA | Human blood sample | in vivo | None | None | Not mentioned | |||
| 8257427 | 1993 | AcSDKP | 4 | Acetylation | Free | Linear | L | None | Human bone marrow | Negative regulator of proliferation of haematopoietic stem cells | Not reported | 1mM | 80 | None | Radioactivity measured with liquid-scintillation counter | Human venous blood sample | in vitro | None | None | Not mentioned | |||
| 8257427 | 1993 | AcSDKP | 4 | Acetylation | Free | Linear | L | None | Human bone marrow | Negative regulator of proliferation of haematopoietic stem cells | Not reported | 10nM conc. | 50 | None | Radioactivity measured with liquid-scintillation counter | Human venous blood sample | in vitro | None | None | Not mentioned | |||
| 8257427 | 1993 | AcSDKP | 4 | Acetylation | Free | Linear | L | None | Human bone marrow | Negative regulator of proliferation of haematopoietic stem cells | Not reported | 10-4M conc | 10 | Rabbit lung angiotensin I converting enzyme | Radioactivity measured with liquid-scintillation counter | Human venous blood sample | in vitro | None | None | Not mentioned | |||
| 8257427 | 1993 | AcSDKP | 4 | Acetylation | Free | Linear | L | None | Human bone marrow | Negative regulator of proliferation of haematopoietic stem cells | Not reported | 10-7M conc. | 25 | Rabbit lung angiotensin I converting enzyme | Radioactivity measured with liquid-scintillation counter | Human venous blood sample | in vitro | None | None | Not mentioned | |||
| 1939259 | 1991 | α-bag cell peptide α-BCP(1-9) | 9 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 26 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-bag cell peptide α-BCP(1-9) | 9 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-6 M conc. of peptide | 35 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(2-9) | 8 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 64 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(1-8) | 8 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 27 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(1-6) | 6 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 11 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(1-5) | 5 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 16 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(3-9) | 7 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 2.1 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(3-9) | 7 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-6 M conc. of peptide | 2.7 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(4-9) | 6 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 2.7 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(5-9) | 5 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 1.5 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(6-9) | 4 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 0.65 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(7-9) | 3 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 9.7 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(3-8) | 6 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 1.5 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(4-8) | 5 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 1.5 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1939259 | 1991 | α-BCP(6-8) | 3 | Free | Free | Linear | L | None | Bag cells in the abdominal ganglion of the marine snail Aplysia | Neurotransmitter | Not reported | 10-5 M conc. of peptide | 0.48 | Aplysia haemolymph proteases | HPLC | Heamolymph of Aplysia | in vitro | None | None | Not given | |||
| 1418002 | 1992 | Somatomedin c | 70 | Free | Free | Linear | L | None | Human liver | Growth hormone | Not given | 129.4 ng | 20 | Human serum proteases | Peptide specific immunoassay | Human serum sample | in vitro | PMID 632300 | None | Somatomedin C is a prerequisite for normal muscle homeostasis which is disrupted in fibromyalgia. Regression analysis shows that ~7 % low level of somatomedin c in case of fibromyalgia patients. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-36)) | 36 | Free | Amidation | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 2.1 ±0.1 (for first phase) | Dog plasma proteases | Radioimmunoassay and HPLC | Intravenous injection to dogs plasma | in vitro | None | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-37)) | 37 | Free | Free | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 2.4 ±0.3 (for first phase) | Dog plasma proteases | Radioimmunoassay and HPLC | Intravenous injection to dogs plasma | in vitro | http://www.anaspec.com/products/product.asp?id=324 | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-36)) | 36 | Free | Amidation | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 68 ±6 (for final phase) | Dog plasma proteases | Radioimmunoassay and HPLC | Intravenous injection to dogs plasma | in vitro | None | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-37)) | 37 | Free | Free | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 81 ±3 (for final phase) | Dog plasma proteases | Radioimmunoassay and HPLC | Intravenous injection to dogs plasma | in vitro | http://www.anaspec.com/products/product.asp?id=324 | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-36)) | 36 | Free | Amidation | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 132 ±16 | Dog plasma proteases | Radioimmunoassay and HPLC | Subcutaneous injection into dog plasma | in vitro | None | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-37)) | 37 | Free | Free | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 61 ±9 | Dog plasma proteases | Radioimmunoassay and HPLC | Subcutaneous injection into dog plasma | in vitro | http://www.anaspec.com/products/product.asp?id=324 | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-36)) | 36 | Free | Amidation | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 449 ±17 | Dog plasma proteases | Radioimmunoassay and HPLC | Subcutaneous injection into dog plasma in presence of bacitracin | in vitro | None | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 8839678 | 1995 | Glucagon like peptide 1 (GLP( 7-37)) | 37 | Free | Free | Linear | L | None | Human intestinal epithelium | Gastric motility | 5, 10, 20, 40, 60, 90, 120, 240, 300 and 360 min | 400 pmol/l | 238 ±35 | Dog plasma proteases | Radioimmunoassay and HPLC | Subcutaneous injection into dog plasma in presence of bacitracin | in vitro | http://www.anaspec.com/products/product.asp?id=324 | None | Bacitracin proteolytoic assay. When plasma sample incubated with 0.1% of bacitracin half life is increased. | |||
| 1824807 | 1991 | naP-2 (Neutrophil-activatingprotein-2) | 70 | Free | Free | Linear | L | None | beta- thromboglobulin | Inflammatory peptide | 48 hours | 20 pmol/site | 65-75 | Rabbit blood proteases | Not mentioned | Intradermal injection in rabbit | in vivo | None | None | P- 2 elicited inflammatory responses (neutrophil emigration, edema formation at 20 pmol/l | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 8 | Rat Stomach luminal flushing proteases | TCA precipitation | Rat Stomach luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 5 | Rat Stomach luminal flushing proteases | Antibody assay | Rat Stomach luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 2.5 | Rat Stomach luminal flushing proteases | Receptor-precipitable radioactivity | Rat Stomach luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Duodenum luminal flushing proteases | TCA precipitation | Rat Duodenum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Duodenum luminal flushing proteases | Antibody assay | Rat Duodenum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Duodenum luminal flushing proteases | Receptor-precipitable radioactivity | Rat Duodenum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Ileum luminal flushing proteases | TCA precipitation | Rat Ileum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Ileum luminal flushing proteases | Antibody assay | Rat Ileum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Ileum luminal flushing proteases | Receptor-precipitable radioactivity | Rat Ileum luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 38 | Rat Colon luminal flushing proteases | TCA precipitation | Rat Colon luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 33 | Rat Colon luminal flushing proteases | Antibody assay | Rat Colon luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | Insulin-like growth factor-I (IGF-I) | 70 | Free | Free | Linear | L | I125 labeling | Human IGF-1 | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 16 | Rat Colon luminal flushing proteases | Receptor-precipitable radioactivity | Rat Colon luminal flushing | in vitro | 632300 | None | Stimulate gut growth and repair | |||
| 7561632 | 1995 | LR(3) insulin-like growth factor-I (IGF-I) | 83 | 13 amino acid extension peptide at the N-terminus of IGF-I | Free | Linear | L | I125 labeling | Analogue of IGF-I | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 50 | Rat Stomach luminal flushing proteases | TCA precipitation | Rat Stomach luminal flushing | in vivo | http://www.cellsciences.com/content/p-detail.asp?r | None | Protect the growth factor by steric hindrance of cleavage sites. | |||
| 7561632 | 1995 | LR(3) insulin-like growth factor-I (IGF-I) | 83 | 13 amino acid extension peptide at the N-terminus of IGF-I | Free | Linear | L | I125 labeling | Analogue of IGF-I | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Duodenum luminal flushing proteases | TCA precipitation | Rat Duodenum luminal flushing | in vivo | http://www.cellsciences.com/content/p-detail.asp?r | None | Protect the growth factor by steric hindrance of cleavage sites. | |||
| 7561632 | 1995 | LR(3) insulin-like growth factor-I (IGF-I) | 83 | 13 amino acid extension peptide at the N-terminus of IGF-I | Free | Linear | L | I125 labeling | Analogue of IGF-I | Growth Hormone | 2-5, 5, 7-5, 10 or 20min | 8.6ng | 2 | Rat Ileum luminal flushing proteases | TCA precipitation | Rat Ileum luminal flushing | in vivo | http://www.cellsciences.com/content/p-detail.asp?r | None | Protect the growth factor by steric hindrance of cleavage sites. | |||
| 7561632 | 1995 | LR(3) insulin-like growth factor-I (IGF-I) | 83 | 13 amino acid extension peptide at the N-terminus of IGF-I | Free | Linear | L | I125 labeling | Analogue of IGF-I | Growth Hormone | 5, 10, 20, 30 or 60 min | 8.6ng | 60 | Rat Colon luminal flushing proteases | TCA precipitation | Rat Colon luminal flushing | in vivo | http://www.cellsciences.com/content/p-detail.asp?r | None | Protect the growth factor by steric hindrance of cleavage sites. | |||
| 7522585 | 1994 | Antagonist D [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-SP | 22 | Free | Free | Linear | Mix | None | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 9 | Mouse liver proteases | RP-HPLC and Electrochemical Detection | Mouse liver homogenate | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist D [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-SP | 22 | Free | Free | Linear | Mix | None | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 10 μg/ml | 4.6 | Mouse liver proteases | RP-HPLC and Electrochemical Detection | Mouse liver homogenate | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist D [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-SP | 22 | Free | Free | Linear | Mix | None | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 11.8 | SCLC proteases | RP-HPLC and Electrochemical Detection | Small cell lung cancer (SCLC) | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist D [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-SP | 22 | Free | Free | Linear | Mix | None | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 10 μg/ml | >24 | SCLC proteases | RP-HPLC and Electrochemical Detection | Small cell lung cancer (SCLC) | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 20.9 | None | RP-HPLC and Electrochemical Detection | Water | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | >24 | None | RP-HPLC and Electrochemical Detection | Acetic acid | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 4.4 | Human plasma proteases | RP-HPLC and Electrochemical Detection | Human plasma | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 14.6 | Mouse liver proteases | RP-HPLC and Electrochemical Detection | Mouse liver homogenate | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 0.1 μg/ml | 22.8 | SCLC proteases | RP-HPLC and Electrochemical Detection | Small cell lung cancer (SCLC) | in vitro | None | None | Act as growth factors | |||
| 7522585 | 1994 | Antagonist G [Arg6, D-Trp7,9, MePhe8] - substance P (6-11) | 17 | Free | Free | Linear | Mix | Methylation of phenylalanine at 3rd position | Substance P (SP) analogue | Anticancer drugs | 1, 2, 5 and 24 hours | 10 μg/ml | >24 | SCLC proteases | RP-HPLC and Electrochemical Detection | Small cell lung cancer (SCLC) | in vitro | None | None | Act as growth factors | |||
| 7529108 | 1994 | Human big endothelin-1 (Human big-ET-1) | 38 | Free | Free | Linear | L | None | Human Endothelin-1 | Vasoconstricting peptide | 180 minute | 3 nmol of peptide with 200 ng of enzyme | 24 (t1/2 of hydrolysis) | Endopeptidase-24.11(E-24.11) | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | Human endothelin-1 (Human ET-1) | 21 | Free | Free | Linear | L | None | Human Endothelin-1 | Vasoconstricting peptide | 180 minute | 3 nmol of peptide with 200 ng of enzyme | 37 (t1/2 of hydrolysis) | Endopeptidase-24.11(E-24.11) | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | C-terminal fragment of Human Endothelin-1 (CTF) | 17 | Free | Free | Linear | L | None | Human Endothelin-1 | Vasoconstricting peptide | 180 minute | 3 nmol of peptide with 200 ng of enzyme | 57 (t1/2 of hydrolysis) | Endopeptidase-24.11(E-24.11) | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | Porcine big endothelin-1 (Porcine big-ET-1) | 39 | Free | Free | Linear | L | None | Porcine Endothelin-1 | Vasoconstricting peptide | 80 minute | 3 nmol of peptide with 50 ng of enzyme | 25 (t1/2 of hydrolysis) | Thermolysin | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | Porcine endothelin-1 (Porcine ET-1) | 21 | Free | Free | Linear | L | None | Porcine Endothelin-1 | Vasoconstricting peptide | 80 minute | 3 nmol of peptide with 50 ng of enzyme | 56 (t1/2 of hydrolysis) | Thermolysin | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | C-terminal fragment of Porcine Endothelin-1 (Porcine CTF) | 18 | Free | Free | Linear | L | None | Porcine Endothelin-1 | Vasoconstricting peptide | 80 minute | 3 nmol of peptide with 50 ng of enzyme | 47 (t1/2 of hydrolysis) | Thermolysin | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | 8269939 | None | Not reported | |||
| 7529108 | 1994 | Substance P | 11 | Free | Free | Linear | L | None | Spinal cord | Vasoconstricting peptide | 180 minute | 3 nmol of peptide with 200 ng of enzyme | 2.1 (t1/2 of hydrolysis) | Endopeptidase-24.11(E-24.11) | Radioimmunoassay and RP-HPLC | Purified ET-1 protein sample | in vitro | None | None | Not reported | |||
| 7689499 | 1993 | Galanin | 30 | Free | Free | Linear | L | None | Human tissue | Neuropeptide | 60 minutes | 74 pmol/kg | 3.7 ±0.4 | Human serum proteases | Radioimmunoassay | Human serum | in vivo | 1370155 | None | Growth hormone concentrations increased markedly during galanin infusion reaching a plateau value eight times the pre-infusion concentrations after 40-min infusion p < 0.01 | |||
| 7714746 | 1994 | Leu-enkephalin | 5 | Free | Free | Linear | L | None | Opoid | Nociception regulating peptide | Not mentioned | 0.10mM, 10 mL | 17.7 | Aminopeptidases present in nasal mucosa of rat | HPLC | Nasal administration to Male Sprague Dawley derived rats | in vivo | None | None | Not reported | |||
| 7714746 | 1994 | Leu-enkephalin | 5 | Free | Free | Linear | L | None | Opoid | Nociception regulating peptide | Not mentioned | 0.10mM, 10 mL | 23.9 | Aminopeptidases present in nasal mucosa of rat | HPLC | Nasal administration to Male Sprague Dawley derived rats | in vivo | None | None | Not reported | |||
| 7714746 | 1994 | Leu-enkephalin analogue | 5 | Free | Free | Linear | L | None | Opoid | Nociception regulating peptide | Not mentioned | 0.10mM, 10 mL | 21.2 | Aminopeptidases present in nasal mucosa of rat | HPLC | Nasal administration to Male Sprague Dawley derived rats | in vivo | None | None | Not reported | |||
| 7957536 | 1994 | Hexarelin | 6 | Free | Amidation | Linear | Mix | Trp methylated at position 2 | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 24 hours | 0.5 μg/kg | 50 | Human serum proteases | Chemiluminescence immunometric assay | Twelve adult male volunteers | in vivo | None | None | Mean ED50 values were 0.50 μg/kg and Emax values were 55.1 μg/kg | |||
| 7957536 | 1994 | Hexarelin | 6 | Free | Amidation | Linear | Mix | Trp methylated at position 2 | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 24 hours | 1 μg/kg | 51 | Human serum proteases | Chemiluminescence immunometric assay | Twelve adult male volunteers | in vivo | None | None | Mean ED50 values were 0.50 μg/kg and Emax values were 55.1 μg/kg | |||
| 7957536 | 1994 | Hexarelin | 6 | Free | Amidation | Linear | Mix | Trp methylated at position 2 | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 24 hours | 2 μg/kg | 58 | Human serum proteases | Chemiluminescence immunometric assay | Twelve adult male volunteers | in vivo | None | None | Mean ED50 values were 0.50 μg/kg and Emax values were 55.1 μg/kg | |||
| 7991443 | 1994 | C-20 Sorbin | 20 | Free | Amidation | Linear | L | None | Derived from Sorbin | Electrolyte absorbing peptide | 1, 2, 4, 8, 16, and 32 min | 200 μg/kg/h | 9.5 ±1.8 | Rat blood proteases | Radioimmunoassay | Male Sprague-Dawley rats blood | in vivo | None | None | Increases absorption of water and ions | |||
| 7991443 | 1994 | C-7 Sorbin | 7 | Free | Amidation | Linear | L | None | Derived from Sorbin | Electrolyte absorbing peptide | 1, 2, 4, 8, 16, and 32 min | 200 μg/kg/h | 7.5 ±1.5 | Rat blood proteases | Radioimmunoassay | Male Sprague-Dawley rats blood | in vivo | None | None | Increases absorption of water and ions | |||
| 7991443 | 1994 | Tritiated C-7 Sorbin | 7 | Free | Amidation | Linear | L | [2-dehydro-Pro1.5]C is attached and tritiated | Derived from Sorbin | Electrolyte absorbing peptide | 1, 2, 4, 8, 16, 32, and 64 min | 2.8 MBq | 17.9 ±1.5 | Rat blood proteases | Radioimmunoassay | Male Sprague-Dawley rats blood | in vivo | None | None | Increases absorption of water and ions | |||
| 8020889 | 1994 | SMS 201-995 (Somatostatin analog octreotide) | 8 | Free | Free | Cyclic (C2-C7) | Mix | None | Somatostatin analogue | Growth Hormone Inhibitor | 2 hours | 2 nmol | 1.2 ±0.2 (elimination half life) | Rat plasma proteases | Liquid scintillation counting | Injected into mesenteric veins rat | in vivo | None | None | Peptides bound with high affinity and specificity to rat cortex membranes with pIC50= 9.53 ± 0.07 | |||
| 8020889 | 1994 | N-α-(α-D-glucosyl(1-4)-1-deoxy-D-fructosyl)-octreotide-SDZ CO-611 | 8 | N-alpha-(alpha-D-glucosyl(1-4)-1-deoxy-D-fructosyl) | Free | Cyclic (C2-C7) | Mix | None | Somatostatin analogue | Growth Hormone Inhibitor | 2 hours | 2 nmol | 1.9 ±0.3 (elimination half life) | Rat plasma proteases | Liquid scintillation counting | Injected into mesenteric veins rat | in vivo | None | None | Peptides bound with high affinity and specificity to rat cortex membranes with pIC50= 9.53 ± 0.08 | |||
| 8076909 | 1994 | Human BNP (Brain natriuretic Peptide) | 32 | Free | Free | Linear | L | None | Human BNP (Brain Natriuretic Peptide) | Diuretic,natriuretic and vasodilatory peptide | Not mentioned | Not mentioned | 20.7 (slow component) | None | Not mentioned | None | in vitro | 2136732 | None | Not reported | |||
| 8076909 | 1994 | Human BNP (Brain natriuretic Peptide) | 32 | Free | Free | Linear | L | None | Human BNP (Brain Natriuretic Peptide) | Diuretic,natriuretic and vasodilatory peptide | Not mentioned | Not mentioned | 3.9 (fast component) | None | Not mentioned | None | in vitro | 2136732 | None | Not reported | |||
| 8076909 | 1994 | Human BNP (Brain natriuretic Peptide) | 28 | Free | Free | Linear | L | None | Human BNP (Brain Natriuretic Peptide) | Diuretic,natriuretic and vasodilatory peptide | Not mentioned | Not mentioned | 13.3 (slow component) | None | Not mentioned | None | in vitro | 6223192 | None | Not reported | |||
| 8076909 | 1994 | Human BNP (Brain natriuretic Peptide) | 28 | Free | Free | Linear | L | None | Human BNP (Brain Natriuretic Peptide) | Diuretic,natriuretic and vasodilatory peptide | Not mentioned | Not mentioned | 1.7 (fast component) | None | Not mentioned | None | in vitro | 6223192 | None | Not reported | |||
| 8082705 | 1994 | Facteur thymique serique | 9 | Free | Free | Linear | L | None | Thymic peptide hormone | Thymic hormone used to treat autoimmune disorder | 5 minutes | 300-500 kBq/kg | 02-Mar | Rats blood proteases | Radioimmunoassay | Intravenouly injected in male Wistar rats | in vivo | 7011613 | None | The basal IRI level at 24 h after alloxan injection was significantly lower in alloxan-treated samples than in controls (12.1 + 5.2 vs. 28.7 + 6.3/zU/ml, P < 0.05) | |||
| 8194082 | 1993 | Epidermal Growth Factor (EGF) | 53 | Free | Free | Linear | L | I125 labeling | Epidermal Growth Factor | Growth factor | 135 minutes | 1420 Ci/mmol | 12.4 (dissociation t1/2) | Proteases present in human meningioma | Autoradiography | Fresh surgically excised human meningioma specimens | in vitro | 4636327 | None | High concentrations (10-4-10 -2 M) of suramin inhibited 125I-EGF binding to meningioma sections with ICs0's of 3.2 + 0.4 × 1 0 - 4 M | |||
| 8289671 | 1994 | Octreotide | 8 | Free | Free | Cyclic (C2-C7) | Mix | None | Somatostatin | Growth Hormone Inhibitor | 60 minutes | 30 ng/kg/min | 90 | Human serum proteases | Not mentioned | Human serum | in vivo | 6128648 | None | It is a potent and well-tolerated inhibitor of basal and stimulated secretion of endogenous insulin, glucagon, and growth hormone when given intravenous infusion at a rate of 30 ng/ kg/min | |||
| 8353526 | 1993 | Trypsin modulating oostatic factor (TMOF) | 10 | Acetylation | Free | Linear | L | None | A. aegypti ovary | Growth regulatory peptide | Not mentioned | Not mentioned | 1.6 | Mosquito ovary endopeptidases | Radioimmunoassay | Ovaries of A. aegypti, Culex quinquefasciatus and Anopheles quadrimaculatus | in vivo | None | None | At concentrations of 3 x 10-9 M and 6.8 x 10-6 M, TMOF inhibited 50 and 90% of trypsin-like enzyme biosynthesis, respectively. | |||
| 8542672 | 1995 | Adrenomedullin (AM) | 50 | Free | Amidation | Linear | L | None | Human pheochromocytoma | Hypotensive peptide | 30 minutes | 1.0 nmol/kg, dissolved in saline | 1.05 ±0.04 | Rat blood proteases | Radioimmunoassay | Spontaneously hypertensive rats (SHR) | in vivo | None | None | The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg. | |||
| 8542672 | 1995 | Adrenomedullin (AM) | 51 | Free | Amidation | Linear | L | None | Human pheochromocytoma | Hypotensive peptide | 30 minutes | 1.0 nmol/kg, dissolved in saline | 1.19 ±0.09 | Rat blood proteases | Radioimmunoassay | Wistar-Kyoto rats | in vivo | None | None | The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were - 12.4, -46.6, -61.6 mmHg. | |||
| 8542672 | 1995 | Adrenomedullin (AM) | 52 | Free | Amidation | Linear | L | None | Human pheochromocytoma | Hypotensive peptide | 30 minutes | 1.0 nmol/kg, dissolved in saline | 18.1 ±1.4 | Rat blood proteases | Radioimmunoassay | Spontaneously hypertensive rats (SHR) | in vivo | None | None | The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg. | |||
| 8542672 | 1995 | Adrenomedullin (AM) | 53 | Free | Amidation | Linear | L | None | Human pheochromocytoma | Hypotensive peptide | 30 minutes | 1.0 nmol/kg, dissolved in saline | 16.3 ±1.2 | Rat blood proteases | Radioimmunoassay | Wistar-Kyoto rats | in vivo | None | None | The mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were - 12.4, -46.6, -61.6 mmHg. | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-1 | 17 | Free | Free | Linear | L | None | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 42 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-2 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 1-2 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 67 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-3 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 3-4 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 43 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-4 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 4-5 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 100 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-5 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 5-6 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | >500 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-6 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 6-7 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 80 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-7 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 7-8 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 192 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-8 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 8-9 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 191 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A (DYN A) analog-9 | 17 | Free | Free | Linear | L | The reduced bond psi [CH,-NH] was introduced at position 9-10 | Opoid | Physiological effect regulating peptide | 0-60 minutes | 100 μM peptide solution to 0.18-ml portions of brain membranes | 93 | Endopeptidase 24-11 (enkephalinase), mouse brain proteases | HPLC | Mouse brain homogenates | in vitro | None | None | Not reported | |||
| 8545255 | 1995 | Hexarelin | 6 | Free | Free | Linear | Mix | Methylated at position 2 of D-trp | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 0.5, 1, 2, 3, 5, 10, 15, 20, 30,40, 60, 80, 120, 150, 240, and 300 min | 1 μg/kg | 119.84 ±22.5 | Dog blood proteases | Radioimmunoassay | Intravenous injection to male and female dogs | in vivo | None | None | Not reported | |||
| 8545255 | 1995 | Hexarelin | 6 | Free | Free | Linear | Mix | Methylated at position 2 of D-trp | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose. | 1 μg/kg | 25 ±5.02 | Dog blood proteases | Radioimmunoassay | Subcutaneous injection to male and female dogs | in vivo | None | None | Not reported | |||
| 8545255 | 1995 | Hexarelin | 6 | Free | Free | Linear | Mix | Methylated at position 2 of D-trp | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose. | 10 μg/kg | 33.3 ±8.83 | Dog blood proteases | Radioimmunoassay | Subcutaneous injection to male and female dogs | in vivo | None | None | Not reported | |||
| 8545255 | 1995 | Hexarelin | 6 | Free | Free | Linear | Mix | Methylated at position 2 of D-trp | Growth hormone-releasing hormone-6 | Growth hormone-releasing peptide | 1, 3, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 120, 150, 180, 240, 300, 360, and 420 min postdose. | 100 μg/kg | 36.7 ±12.01 | Dog blood proteases | Radioimmunoassay | Subcutaneous injection to male and female dogs | in vivo | None | None | Not reported | |||
| 9234336 | 1993 | Vasoactive intestinal peptide (VIP) | 28 | Free | Free | Linear | L | None | Small intestinal mucosa | Vasoactive peptide | 2,3,6,10,20,40,60 minutes | 250 μg | 0.45 ±0.05 | Rat blood proteases | Radioimmunoassay | Intravenous injection to Rat blood | in vivo | http://www.sigmaaldrich.com/catalog/product/sigma/ | None | Regulate of blood flow and smooth muscle relaxation in specific mammalian organs | |||
| 9234336 | 1993 | Vasoactive intestinal peptide (VIP) | 28 | Free | Free | Linear | L | None | Small intestinal mucosa | Vasoactive peptide | 2,3,6,10,20,40,60 minutes | 250 μg | 2.3 ±0.8 | Rat blood proteases | Radioimmunoassay | Intravenous injection to Rat blood | in vivo | http://www.sigmaaldrich.com/catalog/product/sigma/ | None | Regulate of blood flow and smooth muscle relaxation in specific mammalian organs | |||
| 8388403 | 1993 | ANP (Atrial natriuretic Peptide) | 28 | Free | Free | Linear | L | None | Human Heart | Diuretic,natriuretic and vasodilatory peptide | 2 hours | 1.5 pmol/lg/min | 4.1 ±0.4 | Human serum proteases | Radioimmunoassay | Human serum | in vivo | http://www.sigmaaldrich.com/catalog/product/sigma/ | None | No significant differences in systolic blood pressure, diastolic blood pressure or pulse rate were observed when values on active and placebo infusions were compared (P = 0.85) | |||
| 8218482 | 1993 | RGD containing peptide | 5 | Free | Free | Linear | L | None | Extra Cellular Matrix proteins | Antitumor peptide | Not mentioned | 0.2 mL | 30 (t1/2 first phase) | Mice blood proteases | Radioimmunoassay | Intravenously injected to C57BL6 mice | in vivo | None | None | Less effective in in blocking peptide-mediated attachment of B16-FlO melanoma cells to a surface. | |||
| 8218482 | 1993 | RGD containing peptide | 5 | Free | Free | Linear | L | None | Extra Cellular Matrix proteins | Antitumor peptide | Not mentioned | 0.2 mL | 2.7 (t1/2 second phase) | Mice blood proteases | Radioimmunoassay | Intravenously injected to C57BL6 mice | in vivo | None | None | Less effective in in blocking peptide-mediated attachment of B16-FlO melanoma cells to a surface. | |||
| 8218482 | 1993 | RGD containing peptide | 5 | Free | Free | Linear | L | I125 radiolabeling, covalently attached to an isocyanate-containing poly urethane prepolymer | Extra Cellular Matrix proteins | Antitumor peptide | Not mentioned | 0.2 mL | 0.5 (t1/2 first phase) | Mice blood proteases | Radioimmunoassay | Intravenously injected to C57BL6 mice | in vivo | None | None | Less effective in in blocking peptide-mediated attachment of B16-FlO melanoma cells to a surface. | |||
| 8218482 | 1993 | RGD containing peptide | 5 | Free | Free | Linear | L | I125 radiolabeling, covalently attached to an isocyanate-containing poly urethane prepolymer | Extra Cellular Matrix proteins | Antitumor peptide | Not mentioned | 0.2 mL | 11.3 (t1/2 second phase) | Mice blood proteases | Radioimmunoassay | Intravenously injected to C57BL6 mice | in vivo | None | None | Less effective in in blocking peptide-mediated attachment of B16-FlO melanoma cells to a surface. | |||
| 8403527 | 1993 | Calcitonin gene-related peptide (CGRP) | 37 | Free | Free | Linear | L | None | Human Vasopressin | Vasoactive peptide | 2,4,6,8, 10, 15,20,25,30,40,50,60 and 90 min. | Not mentioned | 63.9 ±4.5 | Rat kidney proteases | Not mentioned | Isolated perfused rat kidney | in vivo | http://www.uniprot.org/blast/?about=P06881[83-119] | None | Not reported | |||
| 1319455 | 1992 | hCRH(Human Corticotropin Releasing Hormone) | 41 | Free | Free | Linear | L | None | Derived from Pre-hormone | Hormone causes Adrenocorticotropin secrection and neurotransmitter | 2.5-180 minutes | 100μg | 30.5 ±3.3 | Human plasma proteases | IRM(Immunoradiometric assays) | Human plasma | in vivo | 12379493 | None | 22.4 ± 8.1 ng/hour (ACTH response) | |||
| 1319455 | 1992 | hCRH(Human Corticotropin Releasing Hormone) | 41 | Free | Free | Linear | L | None | Derived from Pre-hormone | Hormone causes Adrenocorticotropin secrection and neurotransmitter | 2.5-180 minutes | 100μg | 46.5 ±7.2 | Sheep plasma proteases | IRM(Immunoradiometric assays) | Human plasma | in vivo | 12379493 | None | 46.5 ± 6.4 ng/hour (ACTH response) | |||
| 1319455 | 1992 | oCRH(Ovine Corticotropin Releasing Hormone) | 41 | Free | Free | Linear | L | None | Derived from Pre-hormone | Hormone causes Adrenocorticotropin secrection and neurotransmitter | 2.5-180 minutes | 100μg | 42.8 ±6.4 | Human plasma proteases | IRM(Immunoradiometric assays) | Sheep plasma | in vivo | 6603620 | None | 39.9 ± 11.7 ng/hour (ACTH response) | |||
| 1319455 | 1992 | oCRH(Ovine Corticotropin Releasing Hormone) | 41 | Free | Free | Linear | L | None | Derived from Pre-hormone | Hormone causes Adrenocorticotropin secrection and neurotransmitter | 2.5-180 minutes | 100μg | 39.8 ±10.1 | Sheep plasma proteases | IRM(Immunoradiometric assays) | Sheep plasma | in vivo | 6603620 | None | 40.2 ± 8.4 ng/hour (ACTH response) | |||
| 1329046 | 1992 | Bombesin | 14 | Free | Amidation | Linear | L | Pyr=Pyro-glutamine | Autocrine peptide of SCLC cell line | Growth stimulator | 0-1080 minutes | 50μM | 417 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 1nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1329046 | 1992 | [Psi13,14]BN [Bombesin antagonist] | 14 | Free | Amidation | Linear | L | Pyr=Pyro-glutamine | Bombesin analogue | Growth inhibitors | 0-1080 minutes | 50μM | 646 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 30nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1329046 | 1992 | [N Psi P]BN(6-14) [Bombesin antagonist] | 9 | Free | Amidation | Linear | Mix | D-Nal =Napthylalanine | Bombesin analogue | Growth inhibitors | 0-1080 minutes | 50μM | 197 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 5nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1329046 | 1992 | [P]BN(6-13)PA [Bombesin antagonist] | 8 | Free | Propylamidation | Linear | Mix | None | Bombesin analogue | Growth inhibitors | 0-360 minutes | 50μM | 559 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 3nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1329046 | 1992 | [P Psi C]BN(6-14) [Bombesin antagonist] | 9 | Free | Amidation | Linear | Mix | Cpa=Chlorophenylalanine | Bombesin analogue | Growth inhibitors | 0-360 minutes | 50μM | 154 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 10nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1329046 | 1992 | [FA]BN(6-13)M [Bombesin antagonist] | 8 | Fluoryl amide | Methy esterification | Linear | Mix | None | Bombesin analogue | Growth inhibitors | 0-1080 minutes | 50μM | 1388 | Degradative enzymes or SCLC cell line proteases | RP-HPLC | SCLC cell line NCI-H345 | in vitro | None | None | IC50= 9nM, Peptide were added at a 1 μM dose to inhibit growth of SCLC cell line | |||
| 1387608 | 1992 | ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Hormone secreted by heart muscle cells | Natriuretic and vasodilator | Blood collected 1-60 minutes after peptide infused | 2μg/min | 12.5 (Terminal half life) | Human plasma proteases | IRM(Immunoradiometric assays) | Young Human plasma (average age 23.3) (Dose i/v injected) | in vivo | None | None | Not reported | |||
| 1387608 | 1992 | ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Hormone secreted by heart muscle cells | Natriuretic and vasodilator | Blood collected 1-60 minutes after peptide infused | 2μg/min | 9.6 (Terminal half life) | Human plasma proteases | IRM(Immunoradiometric assays) | Older Human plasma(average age 75.3) (Dose i/v injected) | in vivo | None | None | Not reported | |||
| 1346149 | 1992 | SS-28 (Somatostatin-28) | 28 | Free | Free | Cyclic (C17-C28) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 228.1 ±76.5 (Metabolic half life) | Brodmann Area tissues proteases | Radioimmunoassay | Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-28 (Somatostatin-28) | 28 | Free | Free | Cyclic (C17-C28) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 257.81 ±86.2(Metabolic half life) | Brodmann Area tissues proteases | Radioimmunoassay | Brodmann Area tissues of brain of SDAT(Medical Research Council Brain Bank, Cambridge, England) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-28 (Somatostatin-28) | 28 | Free | Free | Cyclic (C17-C28) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 260.4 ±129.8 (Metabolic half life) | Hippucampal tissues proteases | Radioimmunoassay | Hippocampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-28 (Somatostatin-28) | 28 | Free | Free | Cyclic (C17-C28) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 335.7 ±100.8 (Metabolic half life) | Hippucampul tissues proteases | Radioimmunoassay | Posterior Hippucampus tissues of brain of SDAT(Medical Research Council Brain Bank, Cambridge, England) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-14 (Somatostatin-14) | 14 | Free | Free | Cyclic (C3-C14) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 140.1 ±36.5 (Metabolic half life) | Brodmann Area tissues proteases | Radioimmunoassay | Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-14 (Somatostatin-14) | 14 | Free | Free | Cyclic (C3-C14) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 129.8 ±53.2(Metabolic half life) | Hippucampul tissues proteases | Radioimmunoassay | Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY) | in vitro | None | None | Not reported | |||
| 1346149 | 1992 | SS-14 (Somatostatin-14) | 14 | Free | Free | Cyclic (C3-C14) | L | None | Hormone produced by neuroendocrine neurons of the ventromedial nucleus of the hypothalamus. | Inhibitor of growth hormone release | 37 °C for 30-180 minutes | 50μM | 79.8 ±11.1(Metabolic half life) | Hippucampul tissues proteases | Radioimmunoassay | Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY) | in vitro | None | None | Not reported | |||
| 1646465 | 1991 | rANP(99-126) (Recombinant atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Derived from ANP (Atrial natriuretic peptide) | Natriuretic and vasodilator | Blood samples collected at 5-1800 seconds after peptide injecteion | Not mentioned | 114 ±38.6 | Rat plasma proteases | Radioimmunoassay | Male Wistar rats plasma | in vivo | None | None | Not reported | |||
| 1646465 | 1991 | iso-rANP(1-45) (Recombinant atrial natriuretic peptide) | 45 | Free | Free | Cyclic (C23-C39) | L | None | Derived from ANP (Atrial natriuretic peptide) | Natriuretic and vasodilator | Blood samples collected at 5-1800 seconds after peptide injecteion | 1 x 106 cpm | 130 ±13 | Rat plasma proteases | Radioimmunoassay | Male Wistar rats plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 1646465 | 1991 | iso-rANP(1-45) (Recombinant atrial natriuretic peptide) | 45 | Free | Free | Cyclic (C23-C39) | L | None | Derived from ANP (Atrial natriuretic peptide) | Natriuretic and vasodilator | Blood samples collected at 5-1800 seconds after peptide injecteion | 1 x 106 cpm | 23.7 + 1.7 (α- t1/2) | Rat plasma proteases | Radioimmunoassay | Male Wistar rats plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 1646465 | 1991 | iso-rANP(1-45) (Recombinant atrial natriuretic peptide) | 45 | Free | Free | Cyclic (C23-C39) | L | None | Derived from ANP (Atrial natriuretic peptide) | Natriuretic and vasodilator | Blood samples collected at 5-1800 seconds after peptide injecteion | 1x 106 cpm | 164.3 ±9.0(β- t1/2) | Rat plasma proteases | Radioimmunoassay | Male Wistar rats plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 1646465 | 1991 | 125I-rANP(1-45) (Recombinant atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | Iodinated at Tyr | Derived from ANP (Atrial natriuretic peptide) | Natriuretic and vasodilator | Blood samples collected at 5-1800 seconds after peptide injecteion | 1 x 106 cpm | 20.2 ±5.3 (α- t1/2) | Rat plasma proteases | Radioimmunoassay | Male Wistar rats plasma (Dose i/p injected) | in vivo | None | None | Not reported | |||
| 1649728 | 1991 | VIP(Vasoactive intestinal peptide) | 28 | Free | Amidation | Linear | L | None | Peptide hormone secreted by Intestine | Stimulates the secretion of electrolytes and water | Sample collected at 40-50 minutes | 10pmol min-1 kg -1 peptide infused | 0.50 ±0.11 | Rabbit plasma proteases | Radioimmunoassay | New Zealand White rabbits plasma(have low sodium diet i.e. 29.35 k 4.02 pmol/l) | in vivo | None | None | Not reported | |||
| 1649728 | 1991 | VIP(Vasoactive intestinal peptide) | 28 | Free | Amidation | Linear | L | None | Peptide hormone secreted by Intestine | Stimulates the secretion of electrolytes and water | Sample collected at 40-50 minutes | 10pmol min-1 kg -1 peptide infused | 1.27 ±0.20 | Rabbit plasma proteases | Radioimmunoassay | New Zealand White rabbits plasma(have normal sodium diet i.e. 29.35 k 4.02 pmol/l) | in vivo | None | None | Not reported | |||
| 1723638 | 1991 | Galanin(1-29) | 29 | Free | Amidation | Linear | L | None | Neuropeptide | Neuroendocrine activities, stimulates growth hormone secretion | 37 °C | 1 μM | 100 | Hypothalamic membrane protaeses | HPLC | Hypothalamic membranes of Male Sprague-Dawley rats | in vitro | None | None | Not reported | |||
| 1723638 | 1991 | Galanin(1-16) | 16 | Free | Free | Linear | L | None | High affinity synthetic agonist | Neuroendocrine activities, stimulates growth hormone secretion | 37 °C | 2 μM | 28 | Hypothalamic membrane protaeses | HPLC | Hypothalamic membranes of Male Sprague-Dawley rats | in vitro | None | None | Not reported | |||
| 1730807 | 1992 | GHRP (Growth Hormone releasing peptide) | 6 | Free | Amidation | Linear | Mix | None | Growth Hormone releasing peptide | Release growth hormone | Not mentioned | 100μg/kg | 20 | Human serum proteases | Radioimmunoassay | Human serum | in vivo | None | None | GH response elicited by 300 μg/kg on oral administeration of peptide | |||
| 1763193 | 1991 | Peptide T (Dala1-peptide T-NH2) | 8 | Free | Amidation | Linear | Mix | None | Synthetic derived from the external envelope protein of HIV IIIB | HIV-entry inhibitor | Not mentioned | Intravenous test dose of 0.033 mg/Kg of peptide T | 30-60 | AIDS patient plasma proteases | Radioimmunoassay , HPLC | AIDS patient plasma | in vivo | None | None | Not reported | |||
| 1826667 | 1991 | GRF(1-29)-NH2 (Growth hormone-releasing factor (GRF- Growth regulating factor)) | 29 | Free | Amidation | Linear | L | None | Growth regulating factor (GRF) | Release growth hormone | Not mentioned | 100 µg/ml | 0.25 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [Ala15]GRF(1-29)-NH2 | 29 | Free | Amidation | Linear | L | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | 0.3 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [DesNH2-Tyr1,Ala15]GRF(1-29)-NH2 | 29 | Chlorpheniramine M | Amidation | Linear | L | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | 1 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [DesNH2-Tyr1,D-Ala2,Ala15]GRF(1-29)-NH2 | 29 | Chlorpheniramine M | Amidation | Linear | Mix | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | 1 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [Asp8,Ala15]Cyclo(Asp8-Lys12)GRF(1-29)-NH2 | 29 | Free | Amidation | Linear | L | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | ~ 4 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [D-Ala2,Asp8,Ala15]Cyclo(Asp8-Lys12)GRF(1-29)-NH2 | 29 | Free | Amidation | Linear | Mix | Cyclo-Asp at 8th position, cyclo-Lys at 12 position | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | >4 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [Ala15 ]Cyclo(Lys21 -Asp 25)GRF(1 -29)-NH2 | 29 | Free | Amidation | Linear | L | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | >4 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [D-Ala2,Ala15]Cyclo(Lys21-Asp25)GRF(1-29)-NH2 | 29 | Free | Amidation | Linear | Mix | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | >4 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1826667 | 1991 | [Asp8,Ala15]Cyclo(Asp8-Lys12)(Lys21-Asp25)GRF(1-29)-NH2 | 29 | Free | Amidation | Linear | L | None | Synthetic(GRF-1 analogs) | Release growth hormone | Not mentioned | 100 µg/ml | >4 | Porcine plasma proteases | HPLC | Porcine plasma | in vitro | None | None | Not reported | |||
| 1889124 | 1991 | CCK58 (Cholecystokinin 58) | 58 | Free | Amidation | Linear | L | None | Peptide hormone of the gastrointestinal system | Stimulates digestion of fat & protein | 37 °C for 30-180 minutes | 1.6pmol | 45 ±5 | Normal Human plasma proteases | Radioimmunoassay and HPLC | Normal Human plasma | in vitro | None | None | Not reported | |||
| 1889124 | 1991 | CCK58 (Cholecystokinin 58) | 58 | Free | Amidation | Linear | L | None | Peptide hormone of the gastrointestinal system | Stimulates digestion of fat & protein | 37 °C for 30-180 minutes | 1.6pmol | 69 ±8 | Normal Human blood proteases | Radioimmunoassay and HPLC | Normal Human blood | in vitro | None | None | Not reported | |||
| 1889124 | 1991 | CCK58 (Cholecystokinin 58) | 58 | Free | Amidation | Linear | L | None | Peptide hormone of the gastrointestinal system | Stimulates digestion of fat & protein | 37 °C for 30-180 minutes | 1.6pmol | 10.4 ±1.1 | Pancreatitis patients blood proteases | Radioimmunoassay and HPLC | Pancreatitis patient plasma | in vitro | None | None | Not reported | |||
| 1889124 | 1991 | CCK58 (Cholecystokinin 58) | 58 | Free | Amidation | Linear | L | None | Peptide hormone of the gastrointestinal system | Stimulates digestion of fat & protein | 37 °C for 30-180 minutes | 1.6pmol | 11.1 ±1 | Pancreatitis patients plasma proteases | Radioimmunoassay and HPLC | Pancreatitis patient blood | in vitro | None | None | Not reported | |||
| 1904406 | 1991 | [Leu27] hGRF( 1-32)NH2 (Growth hormone releasing factor analog) | 32 | Free | Amidation | Linear | L | None | Human growth hormone releasing factor analog | Growth hormone(GH) release | 37 °C, phosphate buffer pH 7.4 | 0.2mM | 202 | Collagenase pancreatin | HPLC | Cultured bovine anterior pituitary cells | in vitro | None | None | EC50=0.24 ± 0.045(GH release) | |||
| 1904406 | 1991 | [Leu27, Asn28]hGRF(I-32)NH2 (Growth hormone releasing factor analog) | 32 | Free | Amidation | Linear | L | None | Human growth hormone releasing factor analog | Growth hormone(GH) release | 37 °C, phosphate buffer pH 7.4 | 0.2mM | 150 | Collagenase pancreatin | HPLC | Cultured bovine anterior pituitary cells | in vitro | None | None | EC50=0.32 ± 0.059(GH release) | |||
| 1904406 | 1991 | [Ser8, Leu27, Asn28]hGRF(I-32)NH2 (Growth hormone releasing factor analog) | 32 | Free | Amidation | Linear | L | None | Human growth hormone releasing factor analog | Growth hormone(GH) release | 37 °C, phosphate buffer pH 7.4 | 0.2mM | 746 | Collagenase pancreatin | HPLC | Cultured bovine anterior pituitary cells | in vitro | None | None | EC50=0.26 ± 0.040(GH release) | |||
| 1904406 | 1991 | [Ser8, Leu27]hGRF(I-32)NH2 (Growth hormone releasing factor analog) | 32 | Free | Amidation | Linear | L | None | Human growth hormone releasing factor analog | Growth hormone(GH) release | 37 °C, phosphate buffer pH 7.4 | 0.2mM | 1550 | Collagenase pancreatin | HPLC | Cultured bovine anterior pituitary cells | in vitro | None | None | EC50=0.44 ± 0.014(GH release) | |||
| 1551497 | 1992 | C-peptide (Connecting peptide) | 31 | Free | Free | Linear | L | None | Pro-insulin derivative | Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling | Blood collected 2-180 minutes after peptide injection | 150 µg of peptide injected | 4.95 ±1.04(short half life or initial decay) | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | Insulin secretion rates can be accurately estimated from plasma levels of C-peptide | |||
| 1551497 | 1992 | C-peptide (Connecting peptide) | 31 | Free | Free | Linear | L | None | Pro-insulin derivative | Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling | Blood collected 2-180 minutes after peptide injection | 150 µg of peptide injected | 32.4 ±5(long half life) | Proteases from Human plasma | Radioimmunoassay | Human plasma | in vivo | None | None | Insulin secretion rates can be accurately estimated from plasma levels of C-peptide | |||
| 1551497 | 1992 | C-peptide (Connecting peptide) | 31 | Free | Free | Linear | L | None | Pro-insulin derivative | Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling | Blood collected 2-180 minutes after peptide injection | 150 µg of peptide injected | 4.55 ±1.23 (short half life or initial decay) | Proteases from Human(obese) plasma | Radioimmunoassay | Human(obese) plasma | in vivo | None | None | Insulin secretion rates can be accurately estimated from plasma levels of C-peptide | |||
| 1551497 | 1992 | C-peptide (Connecting peptide) | 31 | Free | Free | Linear | L | None | Pro-insulin derivative | Connect A- and B-chains of insulin and regulates Ca-dependent cell signaling | Blood collected 2-180 minutes after peptide injection | 150 µg of peptide injected | 32.4 ±5(long half life) | Proteases from Human(obese) plasma | Radioimmunoassay | Human(obese) plasma | in vivo | None | None | Insulin secretion rates can be accurately estimated from plasma levels of C-peptide | |||
| 1651738 | 1991 | alpha-ANP (alpha-atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | alpha-atrial natriuretic peptide | Natriuretic and vasodilator | Blood collected 30-60 minutes during and 5-20 minutes after peptide injection | 0.005 - 0.05 µg/kg/min in 25 mL normal saline infused over 1 h | 4.3 ±0.6 | Proteases from Human plasma(younger, 20-39 years old) | Radioimmunoassay | Human plasma(younger, 20-39 years old) | in vivo | None | None | Natriuresis (145 ±36 ν 142 ± 28 µMol/min) and urinary cGMP excretion (40.9 ± 6.7 nmol/h) | |||
| 1651738 | 1991 | alpha-ANP (alpha-atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | alpha-atrial natriuretic peptide | Natriuretic and vasodilator | Blood collected 30-60 minutes during and 5-20 minutes after peptide injection | 0.005 - 0.05 µg/kg/min in 25 mL normal saline infused over 1 h | 7.8 ±0.6 | Proteases from Human plasma(older, 65-83 years old) | Radioimmunoassay | Human plasma(older, 65-83 years old) | in vivo | None | None | Natriuresis 142 ± 28 µMol/min and urinary cGMP excretion 35.3 ± 4.1 | |||
| 1777964 | 1991 | CLAP(Prpcolipase activation peptide) | 5 | Free | Free | Linear | L | None | Derived from colipase | Procolipase activation peptide | Room Temperature(25C) | 500nM/L | 5 | Proteases from Human serum | ELISA | Human Serum | in vitro | None | None | Not reported | |||
| 1777964 | 1991 | CLAP(Prpcolipase activation peptide) | 5 | Free | Free | Linear | L | None | Derived from colipase | Procolipase activation peptide | Room Temperature(25C) | 0.5 µM | 4 | Proteases from Human urine | ELISA | Human urine | in vitro | None | None | Not reported | |||
| 1831249 | 1991 | ANP(99-126) (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Hormone secreted by heart muscle cells | Natriuretic and vasodilator | Blood collected 2-20 minutes after peptide infused | 5pmol/kg | 4.8 ±0.8 | Proteases from Human plasma (Chronic renal diseases) | Radioimmunoassay | Human plasma (Chronic renal diseases) | in vivo | None | None | GFR and ERPF increased by a mean value of 23% and 27% respectively | |||
| 1882091 | 1991 | GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | L | pGlu= Pyro-glutamate | Hormone secreted by Hypothalamus | Stimulates the release of the gonadotropins from the pituitary. | 37 °C | 40mg/ml | 10.5 | Proteases from Rat ovary tissues | Radioimmunoassay | Rat ovary tissues | in vitro | 1631133 | None | Not reported | |||
| 1882091 | 1991 | GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | L | pGlu= Pyro-glutamate | Hormone secreted by Hypothalamus | Stimulates the release of the gonadotropins from the pituitary. | 37 °C | 40mg/ml | 45 | Proteases from Rat Lung tissues | Radioimmunoassay | Rat lung tissues | in vitro | 1631133 | None | Not reported | |||
| 1882091 | 1991 | GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | L | pGlu= Pyro-glutamate | Hormone secreted by Hypothalamus | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 2.66 (t1/2 alpha) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | L | pGlu= Pyro-glutamate | Hormone secreted by Hypothalamus | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 12.16 (t1/2 beta) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | L | pGlu= Pyro-glutamate | Hormone secreted by Hypothalamus | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 0.69 (t1/2 alpha) | Rat plasma proteases | Radioimmunoassay | (Dose i/m injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | D-Phe-6-GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | Mix | None | GnRH derivative | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 14.53 | Rat plasma proteases | Radioimmunoassay | (Dose i/m injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | D-Phe-6-GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | Mix | None | GnRH derivative | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 0.83 | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | Mix | None | GnRH derivative | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 25.8 (t1/2 beta) | Rat plasma proteases | Radioimmunoassay | (Dose i/v injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1882091 | 1991 | D-Trp3-D-Phe-6-GnRH (Gonadotropin releasing hormone) | 10 | Free | Amidation | Linear | Mix | None | GnRH derivative | Stimulates the release of the gonadotropins from the pituitary. | Blood collected 30-300 minutes after peptide injection | 24 µg/kg | 36.4 | Rat plasma proteases | Radioimmunoassay | (Dose i/m injected)Rat plasma | in vivo | 1631133 | None | Not reported | |||
| 1664804 | 1991 | Rat BNP-45 ( Brain natriuretic peptide-45) | 45 | Free | Free | Cyclic (C23-C39) | L | None | Isolated from rat heart and shown to be a circulating form of rat BNP | Cardiac Natriuretic Peptide | Blood samples collected at 0.5-10 minutes post peptide injection | 2 µg/150ul saline | 45 (t1/2 alpha or initial phase t1/2) | Proteases from Mice (WKY)plasma | Radioimmunoassay | (Dose i/v injected)Mice (WKY) plasma | in vivo | None | None | Urinary sodi µM excretion (uEq/min per kg)= 0.43 ± 0.13, mean arterial pressure (mmHg) = 129 ± 1, Urinary cGMP excretion (pmol/min) = 27.0 ± 3.1 | |||
| 1664804 | 1991 | Rat BNP-45 ( Brain natriuretic peptide-45) | 45 | Free | Free | Cyclic (C23-C39) | L | None | Isolated from rat heart and shown to be a circulating form of rat BNP | Cardiac Natriuretic Peptide | Blood samples collected at 0.5-10 minutes post peptide injection | 2 µg/150ul saline | 6.95 (t 1/2 beta or 2nd phase t1/2) | Proteases from Mice (WKY)plasma | Radioimmunoassay | (Dose i/v injected)Mice (WKY) plasma | in vivo | None | None | Urinary sodi µM excretion (uEq/min per kg)= 0.43 ± 0.13, mean arterial pressure (mmHg) = 129 ± 1, Urinary cGMP excretion (pmol/min) = 27.0 ± 3.2 | |||
| 1664804 | 1991 | Rat alpha-ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic and vasodilator | Blood samples collected at 0.5-10 minutes post peptide injection | 2 µg/150ul saline | 55 (t1/2 alpha or initial phase t1/2) | Proteases from Mice (WKY)plasma | Radioimmunoassay | (Dose i/v injected)Mice (WKY) plasma | in vivo | None | None | Urinary sodi µM excretion (uEq/min per kg)= 0.45 ± 0.10, mean arterial pressure (mmHg) = 129 ± 2, Urinary cGMP excretion (pmol/min) = 28.0 ±2.6 | |||
| 1664804 | 1991 | Rat alpha-ANP (Atrial natriuretic peptide) | 28 | Free | Free | Cyclic (C7-C23) | L | None | Atrial natriuretic peptide | Natriuretic and vasodilator | Blood samples collected at 0.5-10 minutes post peptide injection | 2 µg/150ul saline | 4.03 (t 1/2 beta or 2nd phase t1/2) | Proteases from Mice (WKY)plasma | Radioimmunoassay | (Dose i/v injected)Mice (WKY) plasma | in vivo | None | None | Urinary sodi µM excretion (uEq/min per kg)= 0.43 ± 0.13, mean arterial pressure (mmHg) = 129 ± 1, Urinary cGMP excretion (pmol/min) = 27.0 ± 3.4 | |||
| 8147781 | 1994 | CGRP(Calcitonin gene related peptide) | 37 | Free | Free | Linear | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | 37 °C for 5-60 minutes | 60 µL of 1 nmol/L CGRP | 4.3 ±0.2 | Proteases from sheep plasma | Radioimmunoassay | Sheep plasma before nephrectomy | in vitro | None | None | Not reported | |||
| 8147781 | 1994 | CGRP(Calcitonin gene related peptide) | 37 | Free | Free | Linear | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | 37 °C for 5-60 minutes | 60 µL of 1 nmol/L CGRP | 7.6 ±0.8 | Proteases from sheep plasma | Radioimmunoassay | Sheep plasma after 2 days nephrectomy | in vitro | None | None | Not reported | |||
| 8147781 | 1994 | CGRP(Calcitonin gene related peptide) | 37 | Free | Free | Linear | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | 37 °C for 5-60 minutes | 60 µL of 1 nmol/L CGRP | 7.3 ±0.4 | Proteases from sheep plasma | Radioimmunoassay | Sheep plasma after 5 days nephrectomy | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 0.75 | Proteases from Human serum | HPLC | Human serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 1.3 | Proteases from Human plasma | HPLC | Human plasma | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 1.7 | Proteases from Human blood | HPLC | Human blood | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 0.5 | Proteases from Horse serum | HPLC | Horse serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 3.5 | Proteases from Fetal calf serum | HPLC | Fetal calf serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 1.75 | Proteases from Heat inactivated calf serum | HPLC | Heat inactivated calf serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 4 | Proteases from Mouse serum | HPLC | Mouse serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 7 | Proteases from Human serum | HPLC | Human serum + 1μM catropril | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 5.5 | Proteases from Horse serum | HPLC | Horse serum | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 18 | Proteases from Fetal calf serum | HPLC | Fetal calf serum + 1μM catropril | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 11.5 | Proteases from Heat inactivated calf serum | HPLC | Heat inactivated calf serum + 1μM catropril | in vitro | None | None | Not reported | |||
| 8217216 | 1993 | AcSDKP (Acetyl-SDKP) | 4 | Acetylation | Free | Linear | L | None | Isolated from fetal calf bone marrow | Natural hemoregulatory | 37 °C for 24 hours | 4 X lO-7M, 10 µCi | 6 | Proteases from Mouse serum | HPLC | Mouse serum + 1μM catropril | in vitro | None | None | Not reported | |||
| 8218482 | 1993 | Pentapeptide | 5 | Free | Free | Linear | L | None | Synthetic RGD containing peptide | Cell attachment property | Not mentioned | Not mentioned | 30 (Half life of 1st phase) | Proteases from mouse bood | HPLC | Mouse blood | in vivo | None | None | Not reported | |||
| 8218482 | 1993 | Pentapeptide | 5 | Free | Free | Linear | L | None | Synthetic RGD containing peptide | Cell attachment property | Not mentioned | Not mentioned | 2.7 (Half life of 2nd phase) | Proteases from mouse bood | HPLC | Mouse blood | in vivo | None | None | Not reported | |||
| 8218482 | 1993 | YRGDS-polymer conj µgate(Isocyanate containing polyurethane prepolymer) | 5 | Free | Free | Linear | L | Peptide covalently attached to Isocyanate containing polyurethane prepolymer | Synthetic RGD containing peptide | Cell attachment property | Not mentioned | Not mentioned | 0.5 (Half life of 1st phase) | Proteases from mouse bood | HPLC | Mouse blood | in vivo | None | None | Not reported | |||
| 8218482 | 1993 | YRGDS-polymer conj µgate(Isocyanate containing polyurethane prepolymer) | 5 | Free | Free | Linear | L | Peptide covalently attached to Isocyanate containing polyurethane prepolymer | Synthetic RGD containing peptide | Cell attachment property | Not mentioned | Not mentioned | 11.3(Half life of 2nd phase) | Proteases from mouse bood | HPLC | Mouse blood | in vivo | None | None | Not reported | |||
| 8218482 | 1993 | 125I-YRGDS-polymer conj µgate(Isocyanate containing polyurethane prepolymer) | 5 | Free | Free | Linear | L | Peptide covalently attached to Isocyanate containing polyurethane prepolymer | Synthetic RGD containing peptide | Cell attachment property | Not mentioned | Not mentioned | 7 | Proteases from mouse bood | HPLC | Mouse blood | in vivo | None | None | Not reported | |||
| 8289671 | 1994 | Octreotide | 8 | Free | Free | Cyclic (C2-C7) | Mix | None | Somatostatin analogue | Inhibitor of growth hormone secretion | Blood sample collected after 15-60 minutes | 500 µg/ml | 90 | Proteases from Human plasma | Not mentioned | Human plasma | in vivo | None | None | 30ng/kg/min of peptide suppress C-peptide, Insulin, glucagon and growth hormone conc. Below basal level in islet cell clamp study | |||
| 8353526 | 1993 | TMOF (Trypsin modulatinf oostatic factor) | 10 | Free | Free | Linear | L | None | Hormone is secreted from the ovary of Mosquitoes | Inhibitor of trypsin and chymotrypsin biosynthesis | Not mentioned | 30ng/group | 1.6 | Proteases from A. aegypti blood | RP-HPLC | A. aegypti blood | in vivo | None | None | Not reported | |||
| 8403527 | 1993 | CGRP(Calcitonin gene related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Neuropeptide and alernative spliced product of calcitonon produced by thyroid gland | Vasodilator | Blood sample collected after 2-90 minutes | 1.0 pmol/ml of peptide | 63.9 ±4.5 | Rat plasma proteases and isolated perfused rat kidney | Not mentioned | Rat plasma (+IPRK (isolated perfused rat kidney)filtering) | in vitro | None | None | Not reported | |||
| 8403527 | 1993 | CGRP(Calcitonin gene related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Neuropeptide and alernative spliced product of calcitonon produced by thyroid gland | Vasodilator | Blood sample collected after 2-90 minutes | 1.0 pmol/ml of peptide | >10 | Rat plasma proteases and isolated perfused rat kidney | Not mentioned | Rat plasma (+IPRK (isolated perfused rat kidney)filtering) | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 1 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 42 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 2 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 67 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 3 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 43 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 4 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 100 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 5 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | >500 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 6 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 80 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 7 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 192 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 8 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 191 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545241 | 1995 | Dynorphin A(1-11)-NH2 analogue 9 (DYN A analogue) | 11 | Free | Amidation | Linear | L | None | Human placenta Dynorphin A derivative | Incorporating the nonhydrolyzable [CH2-NH] peptide bond surrogate were tested for their in vitro enzymatic stability in mouse brain homogenates. | 37 °C | 100 µM | 93 | Proteases from mouse brain tissues | HPLC | Mouse brain homogenate | in vitro | None | None | Not reported | |||
| 8545255 | 1995 | Hexarelin | 6 | Free | Amidation | Linear | Mix | None | GHRH analogue | Stimulates growth hormone release | Blood sample collected after 0.5-300 minutes | 1 µg/kg | 120 | Proteases from dog plasma | Radioimmunoassay | (Dose i/v injected)Dog plasma | in vivo | None | None | Not reported | |||
| 9234336 | 1994 | 131I-VIP (Vasoactive intestinal peptide) | 28 | Free | Amidation | Linear | L | Iodinated at Tyr | Neuropeptide | Anti-inflammatory neuropeptide | Blood sample collected after 2-60 minutes of peptide administeration | 250 µg (6MBq in 0.2mL) | 0.44 ±0.05 (elimination half life) | Proteases from rat blood | HPLC | (Dose i/v injected)Rat blood | in vivo | None | None | Not reported | |||
| 9234336 | 1994 | 131I-VIP (Vasoactive intestinal peptide) | 28 | Free | Amidation | Linear | L | Iodinated at Tyr | Neuropeptide | Anti-inflammatory neuropeptide | Organs are collected at 2-60 minutes after administration of drug (by killing organism) | 250 µg (6MBq in 0.2mL) | 2.3 ±0.8 (elimination half life) | Proteases from rat lung tissues | HPLC | (Dose i/v injected)Rat lung tissues | in vivo | None | None | Not reported | |||
| 8542672 | 1995 | Rat adrenomedullin (AM) | 50 | Free | Amidation | Cyclic (C14-C19) | L | None | Member of the calcitonin family of peptides | Hypotensive effect | Blood sample collected after 0.5-20 minutes after drug administration | 1.0nmol/Kg | 1.05 ±0.04 (1st phase elimination life) | Proteases from SHR rat plasma | Radioimmunoassay | Rat(SHR) plasma | in vivo | None | None | Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively | |||
| 8542672 | 1995 | Rat adrenomedullin (AM) | 50 | Free | Amidation | Cyclic (C14-C19) | L | None | Member of the calcitonin family of peptides | Hypotensive effect | Blood sample collected after 0.5-20 minutes after drug administration | 1.0nmol/Kg | 1.19 ±0.09 (1st phase elimination life) | Proteases from WKY rat plasma | Radioimmunoassay | Rat(WKY) plasma | in vivo | None | None | Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively | |||
| 8542672 | 1995 | Rat adrenomedullin (AM) | 50 | Free | Amidation | Cyclic (C14-C19) | L | None | Member of the calcitonin family of peptides | Hypotensive effect | Blood sample collected after 0.5-20 minutes after drug administration | 1.0nmol/Kg | 18.1 ±1.4 (2nd phase elimination life) | Proteases from SHR rat plasma | Radioimmunoassay | Rat(SHR) plasma | in vivo | None | None | Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively | |||
| 8542672 | 1995 | Rat adrenomedullin (AM) | 50 | Free | Amidation | Cyclic (C14-C19) | L | None | Member of the calcitonin family of peptides | Hypotensive effect | Blood sample collected after 0.5-20 minutes after drug administration | 1.0nmol/Kg | 16.3 ±1.2 (2nd phase elimination life) | Proteases from WKY rat plasma | Radioimmunoassay | Rat(WKY) plasma | in vivo | None | None | Mean maximal changes in MBP at doses of 0.3, 1.0 and 3.0nmol/kg of AM were -24.0, -78.5, -92.3mmHg for SHR, and - 12.4, -46.6, -61.6 mmHgfor WKY, respectively | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-60 minutes | 10 µg/L of peptide | 29 ±1 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells | in vitro | None | None | Not reported | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-240 minutes | 10 µg/L of peptide | 244 ±20 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells+ Lisinopril | in vitro | None | None | Not reported | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-60 minutes | 10 µg/L of peptide | 46 ±2 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells+ phosphoramidon | in vitro | None | None | Not reported | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-240 minutes | 10 µg/L of peptide | 381 ±51 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells + Lisinopril +phosphoramidon | in vitro | None | None | Not reported | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-240 minutes | 10 µg/L of peptide | 386 ±52 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells+ Lisinopril +phosphoramidon+amastatin | in vitro | None | None | Not reported | |||
| 8395230 | 1993 | Bradykinin | 9 | Free | Free | Linear | L | None | Endogenous peptide of kinin family | Vasodilator, Inflammatory mediator | 37 °C for 15-240 minutes | 10 µg/L of peptide | 257 ±22 | Neutral endopeptides in Human umbilical vein endothelial cells | Radioimmunoassay | Human umbilical vein endithelial cells + Lisinopril +phosphoramidon+amastain + DL-2-mercaptomethyl- 3-guanidinoethyl thiopropionic acid | in vitro | None | None | Not reported | |||
| 8388403 | 1993 | ile 12-ANP (Atrial natriuretic peptide) | 26 | Free | Free | Cyclic (C5-C21) | L | None | Infusions of atrial natriuretic peptide | Natriuretic and vasodilator | Blood sample collected after 15-240 minutes after peptide administration | 1.5pmol/Kg/min dose of peptide | 4.1 ±0.4 | Proteases from Human plasma | Radioimmunoassay | Human plasma(elder men) | in vivo | None | None | It increases the cGMP approx 3 fold | |||
| 1911217 | 1991 | CGRP (Calcitonin gene-related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | Not mentioned | 300-600pmol | 9.00 (plasma half-life) | Proteases from Human plasma | Not mentioned | Human Plasma | in vivo | None | None | Not reported | |||
| 1911217 | 1991 | CGRP (Calcitonin gene-related peptide) | 37 | Free | Amidation | Cyclic (C2-C7) | L | None | Alernative spliced product of calcitonon produced by thyroid gland | Vasodilator and cause tumor hypoxia | Not mentioned | 300-600pmol | 30 (biological half-life) | Not mentioned | Not mentioned | Human Plasma | in vivo | None | None | Not reported | |||
| 1490668 | 1992 | rhGH(Recombinant DNA derived human growth hormone) | 191 | Free | Free | Linear | L | None | Recombinant DNA derived human growth hormone | Promotes growth and development | Not mentioned | 4 IU rhGH/m2 BSA | 18 | Proteases from Human serum | Radioimmunoassay | (Intravenous route of injection) human serum | in vivo | None | None | In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight. | |||
| 1490668 | 1992 | rhGH(Recombinant DNA derived human growth hormone) | 191 | Free | Free | Linear | L | None | Recombinant DNA derived human growth hormone | Promotes growth and development | Not mentioned | 4 IU rhGH/m2 BSA | 2.59 ±1.32 | Proteases from Human serum | Radioimmunoassay | (Subcutaneous route of injection) human serum | in vivo | None | None | In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight. | |||
| 1490668 | 1992 | rhGH(Recombinant DNA derived human growth hormone) | 191 | Free | Free | Linear | L | None | Recombinant DNA derived human growth hormone | Promotes growth and development | Not mentioned | 10 IU rhGH/m2 BSA | 4.29 ±1.89 | Proteases from Human serum | Radioimmunoassay | (Subcutaneous route of injection) human serum | in vivo | None | None | In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight. | |||
| 1490668 | 1992 | rhGH(Recombinant DNA derived human growth hormone) | 191 | Free | Free | Linear | L | None | Recombinant DNA derived human growth hormone | Promotes growth and development | Not mentioned | 4 IU rhGH/m2 BSA | 6.06 ±2.64 | Proteases from Human serum | Radioimmunoassay | (Intramuscular route of injection)human serum | in vivo | None | None | In a GH-deficient child, hGH serum levels between 10 and 20 ng/ml were demonstrated for a period of 8 h after s.c. administration of 0.07 IU rhGH/kg body weight. | |||
| 7994807 | 1994 | Prothrombin fragment 1.2 | 273 | Free | Free | Linear | L | None | Prothrombin | Not mentioned | Not reported | Not reported | 90 | Human blood proteases in presence of Hirudin (anti-coagulant) | Radioimmunoassay ,ELISA | Human blood plasma sample | in vivo | 3759958, 2824564 | None | Not mentioned | |||
| 7787827 | 1994 | 125I-β-NGF | 120 | Free | Free | Cyclic (3 disulphide bonds between C15-C80, C58-C108, C68-C110) | L | None | β-nerve growth factor | Nerve growth promoting peptide | Blood samples (250 µl) were obtained from the catheterized carotid artery 15, 30, 45 and 60 min afte | 800 000 cpm of 125I-7S-NGF or 125I-β-NGF (diluted in 200 µl of saline) | 36.3 + 2.20 | Rats blood proteases | Column chromatography | Intravenouly injected in adult male Wistar rats | in vivo | http://www.drugbank.ca/drugs/DB00188 | None | Not reported | |||
| 7962302 | 1994 | GHRH | 29 | Free | Amidation | Linear | L | None | Synthetic | Growth hormone-releasing hormone (GHRH) stimulates growth hormone (GH) gene transcription, synthesis, and secretion of growth hormone via growth hormone-releasing hormone receptor (GHRH-R) | Blood samples were obtained at 5 min intervals for measurement of serum GH concentrations and at the | Intravenous dose of 1 µg/kg followed by a 15 min infusion of saline in human subjects. | 18.5 ±0.8 | Human blood proteases | Immunoradiometric assay (IRMA) | Human blood | in vivo | http://www.drugbank.ca/drugs/DB00189 | None | Not reported | |||
| 7899230 | 1994 | Leucine enkephalin | 5 | Free | Free | Linear | L | None | Leucine enkephalin | Opioid peptide | Not reported | 0.63 mg/ml | 40 | Sheep nasal wash fluid proteases | HPLC | Sheep nasal wash fluid | in vitro | http://www.drugbank.ca/drugs/DB00190 | None | Not reported | |||
| 7899230 | 1994 | Leucine enkephalin | 5 | Free | Free | Linear | L | None | Leucine enkephalin | Opioid peptide | Not reported | 20 µg/ml | 12 | Sheep nasal mucosal proteases | HPLC | Sheep nasal mucosal tissue homogenate | in vitro | http://www.drugbank.ca/drugs/DB00191 | None | Not reported | |||
| 7899230 | 1994 | des-tyrosine leucine enkephalin | 4 | Free | Free | Linear | L | None | des-tyrosine leucine enkephalin | Opioid peptide | Not reported | 0.63 mg/ml | 13 | Sheep nasal wash fluid proteases | HPLC | Sheep nasal wash fluid | in vitro | http://www.drugbank.ca/drugs/DB00192 | None | Not reported | |||
| 7899230 | 1994 | des-tyrosine leucine enkephalin | 4 | Free | Free | Linear | L | None | des-tyrosine leucine enkephalin | Opioid peptide | Not reported | 20 µg/ml | 7 | Sheep nasal mucosal proteases | HPLC | Sheep nasal mucosal tissue homogenate | in vitro | http://www.drugbank.ca/drugs/DB00193 | None | Not reported | |||
| 8100840 | 1993 | Somatostatin (SOM) | 14 | Free | Free | Cyclic (C3-C14) | L | None | Synthetic | Growth hormone inhibiting hormone (GHIH) | Not reported | Not reported | <5 | Rats blood proteases | Not mentioned | Rats plasma | in vivo | http://www.drugbank.ca/drugs/DB00194 | None | Not reported | |||
| 8100840 | 1993 | Neuropeptide Y | 36 | Free | Amidation | Linear | L | None | Neuropeptide | Stimulation of the right cardiac sympathetic nerve | Not reported | Not reported | 21 | Dogs blood proteases | Not mentioned | Dogs plasma | in vivo | http://www.drugbank.ca/drugs/DB00195 | None | Not reported | |||
| 8082705 | 1994 | Facteur thymique serique (FTS) | 9 | Free | Free | Linear | L | None | Thymic peptide hormone | Suppressed hyperglycemia | Not reported | Not reported | 2 to 3 | Rats blood proteases | Radioimmunoassay | Intravenouly injected in male Wistar rats | in vivo | http://www.drugbank.ca/drugs/DB00196 | None | Plasma glucose in FTS-treated group=15.7 ± 1.8 (mmol/l)while in control Plasma glucose=28.3 ±2.1 ( µmol/l) | |||
| 8035644 | 1994 | Adrenomedullin (ADM) | 52 | Free | Free | Linear | L | None | Synthetic | Hormone in circulation control | Not reported | Intraarterial doses of 0.01-0.3 nmol | 55 to 80 | Cat blood proteases | HPLC | Hind limb vascular bed of the cat | in vivo | http://www.drugbank.ca/drugs/DB00197 | None | Not reported | |||
| 8035644 | 1994 | ADM 15-22 | 8 | Free | Free | Linear | L | None | Carboxy terminal 15-52 fragment of adrenomedullin | An inhibitor of the cellular actions of adrenomedullin | Not reported | Intraarterial doses of 0.01-0.3 nmol | 55 to 80 | Cat blood proteases | HPLC | Hind limb vascular bed of the cat | in vivo | http://www.drugbank.ca/drugs/DB00198 | None | Not reported | |||
| 8035644 | 1994 | Bradykinin | 9 | Free | Free | Linear | L | None | Not mentioned | A potent endothelium-dependent vasodilator which leads to drop in blood pressure | Not reported | Intraarterial doses of 0.01-0.3 nmol | 20 to 45 | Cat blood proteases | HPLC | Hind limb vascular bed of the cat | in vivo | http://www.drugbank.ca/drugs/DB00199 | None | Not reported | |||
| 8353280 | 1993 | Interleukin-3 (IL-3) | 140 | Free | Free | Cyclic (C17-C80,C79-C140) | L | Glycosylation at 84thand 112th position | IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils | Hematopoietic growth factor | Not mentioned | 1,000 biologic units | 2.1 (α half life) | Balb/c mice blood proteases | ELISA | Injected intravenously in Balb/c mice blood | in vivo | http://www.uniprot.org/uniprot/P01586 | None | Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field | |||
| 8353280 | 1993 | Interleukin-3 (IL-3) | 140 | Free | Free | Cyclic (C17-C80,C79-C140) | L | Glycosylation at 84thand 112th position | IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils | Hematopoietic growth factor | Not mentioned | 1,000 biologic units | 10.0 (β half life) | Balb/c mice blood proteases | ELISA | Injected intravenously in Balb/c mice blood | in vivo | http://www.uniprot.org/uniprot/P01586 | None | Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field | |||
| 8353280 | 1993 | Interleukin-3 (IL-3) | 140 | Free | Free | Cyclic (C17-C80,C79-C140) | L | Glycosylation at 84thand 112th position | IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils | Hematopoietic growth factor | Not mentioned | 1,000 biologic units | 3.6 (α half-life) | Balb/c mice blood proteases | ELISA | Injected intravenously in Balb/c mice blood | in vivo | http://www.uniprot.org/uniprot/P01586 | None | Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field | |||
| 8353280 | 1993 | Interleukin-3 (IL-3) | 140 | Free | Free | Cyclic (C17-C80,C79-C140) | L | Glycosylation at 84thand 112th position | IL3 is produced by activated T lymphocytes, activated mast cells, and eosinophils and neutrophils | Hematopoietic growth factor | Not mentioned | 1,000 biologic units | 30.8 (β half life) | Balb/c mice blood proteases | ELISA | Injected intravenously in Balb/c mice blood | in vivo | http://www.uniprot.org/uniprot/P01586 | None | Mice treated with IL3 had megakaryocyte frequency=0.9 ±0.21 per high-power field while saline control had 1.4 ±0.33 per high-power field |